Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study

Background: Although a full course of coronavirus disease 2019 (COVID-19) vaccine is effective in cancer patients, the duration of the protection and the efficacy of a booster dose against the new variants remain unknown. We prospectively evaluated the immunogenicity of the third dose of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BNT162b2 messenger RNA vaccine in cancer patients undergoing active treatment. Patients and methods: Patients with solid cancer, vaccinated with a booster dose during active treatment, were enrolled in this study. Patients were classified into SARS-CoV-2 naïve (without previous COVID-19 infection) and SARS-CoV-2 experienced (with previous COVID-19 infection). Neutralizing antibody (NT Ab) titer and total anti-Spike immunoglobulin G (IgG) concentration were quantified in serum. Heparinized whole blood samples were used for SARS-CoV-2 Interferon Gamma Release Assay (IGRA). The primary endpoint was to assess the increase of IgG antibody level between baseline and 3 weeks after the booster. Results: One hundred and forty-two consecutive patients were recruited. In SARS-CoV-2-naïve subjects, the median level of IgG was 157 BAU/ml [interquartile range (IQR) 62-423 BAU/ml] at T0 and reached a median of 2080 BAU/ml (IQR 2080-2080 BAU/ml) at 3 weeks after booster administration (T1; P < 0.0001). A median 16-fold increase of SARS-CoV-2 NT Ab titer (IQR 4-32) was observed in naïve subjects (from median 20, IQR 10-40, to median 640, IQR 160-640; P < 0.0001). Median interferon-γ level at T1 was significantly higher than that measured at T0 in SARS-CoV-2-naïve subjects (P = 0.0049) but not in SARS-CoV-2-experienced patients. The median level of SARS-CoV-2 NT Abs was 32-fold lower against Omicron compared to the wild-type strain (P = 0.0004) and 12-fold lower compared to the Delta strain (P = 0.0110). Conclusions: The third dose is able to trigger both the humoral and the cell-mediated immune response in cancer patients on active treatment. Our preliminary data about the neutralization of the SARS-CoV-2 vaccine against variants of concern seem to confirm the lower vaccine activity

Torque teno virus and cancers: current knowledge

Plain language summaryTorque teno virus (TTV) is detectable in up to > 90% of healthy people. It has been detected in various types of samples such as blood, serum, breast milk, cerebrospinal fluid and saliva, as well as in various types of tissue such as vagina and hepatocytes. TTV DNAemia is relatively stable in the healthy infected individuals, while TTV viral load is inversely correlated with the number and functions of T lymphocytes in the immunocompromised populations. The role of TTV in the pathogenesis of cancer and in the response to anticancer treatments is not well-known. The aim of this review is to assess the current knowledge about the relationship between TTV and cancer to define the potential key role of TTV in the oncological setting.Tweetable abstractTTV has proven its role of marker for functional immune competence in the setting of hematopoietic stem cell transplantation, but in the oncological field is yet to be defined.Aim: The aim of this systematic review is to assess the current knowledge about the relationship between Torque teno virus (TTV) and cancer in different settings. Methods: A systematic search was conducted in Medline via PubMed, Embase and Cochrane Library from the inception to the end of January 2023. Results: 34 articles were included in the qualitative synthesis of this review and 2145 patients with solid tumors have been analyzed. The most prevalent cancer types were hepatocellular carcinoma (HCC) and lung cancer. Conclusion: TTV has proven its role as a marker of functional immune competence in the setting of hematopoietic stem cell transplantation (HSCT), but in the oncological field is yet to be defined

The development of a self-efficacy scale for nurses to assess the nutritional care of older adults: A multi-phase study

Background & aims: A self-efficacy scale for nurses to assess nutritional care of older adults is pivotal for the development of precise educational interventions designed to promote behavioral changes among nurses by enhancing their self-efficacy. However, self-efficacy measurements associated with nutrition care is currently difficult due to the lack of valid and reliable tools. Therefore, this study aimed to develop and validate a self-efficacy scale for nursing nutritional care. Methods: A multi-method and multi-phase design was adopted. Phase one comprised developmental tasks to generate scale items, based on emerging themes in the literature. Phase two comprised the validation, during which its content, construct, and concurrent validity and internal consistency were assessed. For determining construct validity, phase two encompassed two sequential cross-sectional data collection: the first data collection was designed to assess the psychometric characteristics of the scale, whereas the second aimed to confirm the emerging latent structure of the scale. Results: The final version of the developed scale encompassed 27 items, within three domains, including knowledge (regarding nutritional care), assessment and evidence utilization, and care delivery. The scale exhibited evidence of face and content validity, adequate construct and concurrent validity, and good internal consistency. Conclusions: This study resulted in the development of a tool that could be strategically employed for clinical and educational research aimed at improving the quality of nutritional care by enhancing nursing self-efficacy. The developed scale can provide relevant insights for describing nursing competence and its associations with patient-related outcomes

Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern

Background: The role and the durability of the immunogenicity of the third dose of vaccine against COVID-19 variants of concern in cancer patients have to be elucidated. Patients and methods: We have prospectively evaluated the immunogenicity of the third dose of the SARS-CoV-2 BNT162b2 messenger RNA vaccine in triggering both humoral and cell-mediated immune response in patients with solid tumors undergoing active treatment 6 months after the booster. Neutralizing antibody (NT Ab) titers and total anti-spike immunoglobulin G concentrations were measured in serum. Heparinized whole blood samples were used for the SARS-CoV-2 interferon-γ release assay (IGRA). Results: Six months after the third dose only two patients (2.4%) showed negative spike-specific immunoglobulin G antibody levels (<33.8 BAU/ml). The median level of SARS-CoV-2 NT Abs decreased and only 39/83 (47%) subjects showed maximum levels of NT Abs. T-cellular positive response was observed in 38/61 (62.3%) patients; the highest median level of response was observed 21 days after the third dose (354 mIU/ml, interquartile range 83.3-846.3 mIU/ml). The lowest median level of NT Ab response was observed against the Omicron variant (1 : 10, interquartile range 1 : 10-1 : 40) with a significant reduced rate of responder subjects with respect to the wild-type strain (77.5% versus 95%; P = 0.0022) and Delta variant (77.5% versus 93.7%; P = 0.0053). During the follow-up period, seven patients (8%) had a confirmed post-vaccination infection, but none of them required hospitalization or oxygen therapy. Conclusions: Our work highlights a significant humoral and cellular immune response among patients with solid tumors 6 months after the third BNT162b2 vaccine dose, although a reduction in neutralizing activity against Omicron was observed